STC Biologics, Inc., a privately-held biotechnology company specializing in biosimilar development, announced today that it entered into a $2.5-million Phase II SBIR contract with the National Cancer Institute (NCI) to develop a biosimilar version of a monoclonal antibody for the treatment of cancer. The NCI funding will create at least seven new jobs at the company in Massachusetts. The MLSC wrote a letter of support to supplement STC Biologics’ application for the SBIR Phase II funding. STC Biologics has also hired eight interns through the MLSC’s “Internship Challenge” program.
